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EDITORIAL
Post-operative radiotherapy in non-small-cell lung cancer: more questions
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The value of post-operative radiotherapy as an adjuvant to
surgery for patients with non-small-cell lung cancer still
remains to be proven in a disease which is still at present a
major cause ofcancer death in man. It is, therefore, with regret
that one has to conclude that the publication in this issue
(Medical Research Council Lung Cancer Working Party, 1996)
has not answered this relevant question, as the authors have
approached this question yet again in a small randomised trial.
This is the more frustrating as it is already the sixth trial in
succession which is open to criticism, i.e. a limited number of
patients have been entered, low radiation doses have been used,
there were a large number of ineligible patients, there was
inappropriate staging and no quality assurance programme to
guarantee adequate treatment. It is remarkable, however, to see
that an improvement in time to definite local recurrence and
distant metastases is observed in N2 patients where only 36%
of the 154 patients allocated to radiotherapy received the
treatment as specified in the protocol.
The question of the value of post-operative radiotherapy
needs, however, to be answered more adequately. Even a
small benefit in survival ranging from 5-10% would already
rescue a large number of patients in absolute terms. To be
able to prove or disprove an improvement of between 5 and
10% in 5-year survival, one needs to randomise at least 1000
to 4000 patients (Freedman, 1982). Much larger numbers are
required if one plans to perform subgroup analysis, as the
authors have done. To identify subgroups, such as N2
patients, who will benefit most from this adjuvant approach,
one would need a few thousand patients.
Despite these comments, the authors deserve credit for
having pursued a randomised trial in an area where no
major progress has been seen during the last decades.
Although the trial lacks statistical power to prove or
disprove a survival benefit, it has shown a significant
improvement in time to definite local recurrence and the
appearance of distant metastases. It is obvious that
improvement in local control is beneficial in patients with
lung cancer, as will be acknowledged by physicians who deal
daily with these patients and often fail to reduce symptoms
of airway obstruction. It is even remarkable that this present
trial was able to demonstrate an improvement in local
control with the low radiation dose given and a suboptimal
technique. One should also recognise here that, recently, a
number of lung cancer trials have been published showing
that improved local control has resulted in a higher survival
rate. These trials even included patients with more advanced
disease and therefore a higher risk of distant metastases than
the trial published in this issue. This improvement in local
control has been reached, for example, by modifying the
radiation effects by dose escalation (Cox et al., 1991) or the
daily addition of cisplatin (Schaake-Koning et al., 1992) or
acceleration of the radiation treatment by reducing the
overall treatment time from 6 to 2 weeks (MI Saunders,
personal communication).
Unless a trial of appropriate size is organised to assess the
effect of post-operative radiotherapy on local control and its
impact on survival, the question will remain unanswered.
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